Pancreatic Cancer Research

ResearcherUniversity of GrazNo recent work listed

Peter Kornprat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3114-4579; OpenAlex author ID A5002050163. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2013: 4 papers · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 1 paper, 1 trial · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper

Papers 17

  1. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  2. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Co-author DOI 10.1002/cam4.3233↗
  3. Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12051154↗
  4. The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers12071798↗
  5. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer. Co-author DOI 10.1515/cclm-2018-0016↗
  6. The Predictive Value of the CRP-to-Albumin Ratio for Patients With Pancreatic Cancer After Curative Resection: A Retrospective Single Center Study. Last author DOI 10.21873/invivo.11706↗
  7. Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis. Co-author DOI 10.1007/s00508-018-1383-3↗
  8. Portal vein resection in advanced pancreatic adenocarcinoma: is it worth the risk? Last author DOI 10.1007/s00508-016-1024-7↗
  9. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. Co-author DOI 10.1136/jclinpath-2014-202451↗
  10. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Co-author DOI 10.1515/cclm-2014-0447↗
  11. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. Co-author DOI 10.1007/s00268-013-2283-3↗
  12. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Co-author DOI 10.1038/bjc.2013.701↗
  13. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0104730↗
  14. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Co-author DOI 10.1038/bjc.2013.332↗
  15. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer Co-author DOI 10.1038/bjc.2013.591↗
  16. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. Co-author DOI 10.1136/jclinpath-2012-201394↗
  17. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0078225↗

Trials 1

  1. High-dose Vitamin D3 in Pancreas Cancer Principal investigator NCT03472833↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Stotz · 13 shared papers, 2013–2020 · strength 0.76
  2. Armin Gerger · 13 shared papers, 2013–2020 · strength 0.76
  3. Martin Pichler Pichler · 13 shared papers, 2013–2020 · strength 0.76
  4. Joanna Szkandera · 11 shared papers, 2013–2020 · strength 0.56
  5. Eva Valentina Klocker · 4 shared papers, 2019–2020 · strength 0.39
  6. Konstantin Schlick · 4 shared papers, 2018–2020 · strength 0.36
  7. Jakob Michael Riedl · 3 shared papers, 2020 · strength 0.30
  8. Dominik Andreas Barth · 3 shared papers, 2020 · strength 0.30
  9. Gerald Höefler · 6 shared papers, 2013–2015 · strength 0.21
  10. Katharina Marsoner · 2 shared papers, 2016–2019 · strength 0.19
  11. Eva Asamer · 2 shared papers, 2018–2020 · strength 0.17
  12. Anna Lena Lembeck · 2 shared papers, 2018–2019 · strength 0.16
  13. Jovana Vujić · 1 shared paper, 2019 · strength 0.12
  14. Katharina Beyer · 1 shared paper, 2021 · strength 0.09
  15. Jin Peng He · 1 shared paper, 2021 · strength 0.09
  16. Alessandra Pulvirenti · 1 shared paper, 2021 · strength 0.09
  17. Dimitris Bertsimas Ioannis · 1 shared paper, 2021 · strength 0.09
  18. Hideo Baba · 1 shared paper, 2021 · strength 0.09
  19. Michael Ian D'Angelica · 1 shared paper, 2021 · strength 0.09
  20. Carsten Kamphues · 1 shared paper, 2021 · strength 0.09
  21. Hendrik Seeliger · 1 shared paper, 2021 · strength 0.09
  22. Jacob L. van Dam · 1 shared paper, 2021 · strength 0.09
  23. Caitlin A. McIntyre · 1 shared paper, 2021 · strength 0.09
  24. Alessandro Zerbi · 1 shared paper, 2021 · strength 0.09
  25. Katsunori Imai · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.